RUNX1 and myeloid neoplasm: Nevertheless, the overall incidence of myeloid neoplasm related to this variant was remarkably lower than that described for RUNX1-mutated patients [39], since only 4% of the heterozygous mice (1/25) and 8% of the homozygous mice (2/25) developed the aberrant phenotype, compared to the 44% leukemic progression in FPD/AML patients described in the literature [1].